Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Sands, BE
  • Moss, AC
  • Armuzzi, A
  • Marshall, John Kenneth
  • Lindsay, JO
  • Sandborn, WJ
  • Danese, S
  • Zeroncio, M
  • Modesto, I
  • Salese, L
  • Lawendy, N
  • Zhang, H
  • Su, C

publication date

  • January 1, 2020